Transition Therapeutics reported it will halt development of an experimental drug for patients with type 2 diabetes after a clinical trial of the agent failed to meet its efficacy endpoints. The study was investigating the gastrin analogue TT-223 in combination with a GLP-1 analogue from Eli Lilly. Transition CEO Tony Cruz noted that although "TT-223 has shown efficacy through development, these results indicate that it does not have the product profile for a diabetes therapy."
Reference Articles
Transition Therapeutics stops diabetes drug development - (CNBC)
Transition halts development of lead diabetes candidate (free preview) - (The Wall Street Journal)
Clinical study of TT-223 in combination with a GLP-1 analogue does not meet study efficacy endpoints - (Transition Therapeutics)
**published in "First Word"
No comments:
Post a Comment